The impact of CYP3A4 and CYP3A5 polymorphisms on anastrozole's pharmacokinetics and pharmacodynamics in post-menopausal breast cancer patients

Breast cancer is the second most frequent cancer among all cancer types and is by far the commonest cancer in women. Anastrozole is one of the first line drugs of choice in the treatment of breast cancer and is believed to be superior to tamoxifen. However, a significant proportion of patients tr...

Full description

Saved in:

Bibliographic Details
Main Author:	Abubakar, Murtala Bello
Format:	Thesis
Language:	English
Published:	2017
Subjects:	RG Gynecology and obstetrics
Online Access:	http://eprints.usm.my/43133/1/Dr._Murtala_Bello_Abubakar-24_pages.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my-usm-ep.43133
record_format	uketd_dc
spelling	my-usm-ep.431332019-04-12T05:25:00Z The impact of CYP3A4 and CYP3A5 polymorphisms on anastrozole's pharmacokinetics and pharmacodynamics in post-menopausal breast cancer patients 2017-05 Abubakar, Murtala Bello RG Gynecology and obstetrics Breast cancer is the second most frequent cancer among all cancer types and is by far the commonest cancer in women. Anastrozole is one of the first line drugs of choice in the treatment of breast cancer and is believed to be superior to tamoxifen. However, a significant proportion of patients treated with anastrozole experienced recurrences of breast cancer or developed severe adverse drug reactions. This interpatient variability is attributed to a number of factors such as genetic variations. Anastrozole is predominantly metabolized by CYP3A4 and CYP3A5 enzymes. The objective of this study was to determine the impact of CYP3A4 and CYP3A5 genetic polymorphisms on anastrozole’s pharmacokinetics and pharmacodynamics in postmenopausal breast cancer women. A total of 94 postmenopausal breast cancer women were recruited for this study. Patients’ socio-demographic data and clinical variables were recorded and blood samples were collected for DNA acquisition, hormonal and anastrozole serum levels. Genotyping of CYP3A418A and CYP3A53 was performed using the conventional polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), while that of CYP3A44, CYP3A418B and CYP3A422 was carried out by a novel multiplex PCR-RFLP method. Serum anastrozole concentration was determined by an ultra-high performance liquid chromatography (UHPLC) method using a simple solid-phase extraction procedure. Our study reported that CYP3A418B G>A has a high frequency (0.48) among Malaysians and that CYP3A418A T>C and CYP3A53A>G occur in low (0.03) and high (0.64) frequencies respectively among Malaysians. No variant alleles of CYP3A44 and CYP3A422 were detected among all the subjects. Patients homozygous for CYP3A418B G>A and CYP3A53 A>G had lower and higher anastrozole serum levels respectively compared to those having the respective wild types or heterozygous variants. The multiplex PCR-RFLP method for the simultaneous detection of CYP3A44 A>G, CYP3A418B G>A and CYP3A422 C>T, was applied in genotyping of all the subjects. The newly developed UHPLC method demonstrated a good linearity over concentration ranges of 20 – 1600 ng/mL. The mean recovery for anastrozole was 88.17% with a limit of quantitation of 20 ng/ml. Variables such as patients’ age and time since commencement of anastrozole therapy were associated with higher risk of developing vasomotor symptoms and mood disturbances and/or vaginal dryness/dyspareunia respectively. No significant association was established between CYP3A4 and CYP3A5 genetic polymorphisms and anastrozole’s pharmacodynamics. The detected CYP3A418B G>A and CYP3A5*3 A>G alleles may serve as an important biomarkers of altered anastrozole metabolism in breast cancer patients receiving anastrozole in future. 2017-05 Thesis http://eprints.usm.my/43133/ http://eprints.usm.my/43133/1/Dr._Murtala_Bello_Abubakar-24_pages.pdf application/pdf en public phd doctoral Universiti Sains Malaysia Pusat Pengajian Sains Perubatan
institution	Universiti Sains Malaysia
collection	USM Institutional Repository
language	English
topic	RG Gynecology and obstetrics
spellingShingle	RG Gynecology and obstetrics Abubakar, Murtala Bello The impact of CYP3A4 and CYP3A5 polymorphisms on anastrozole's pharmacokinetics and pharmacodynamics in post-menopausal breast cancer patients
description	Breast cancer is the second most frequent cancer among all cancer types and is by far the commonest cancer in women. Anastrozole is one of the first line drugs of choice in the treatment of breast cancer and is believed to be superior to tamoxifen. However, a significant proportion of patients treated with anastrozole experienced recurrences of breast cancer or developed severe adverse drug reactions. This interpatient variability is attributed to a number of factors such as genetic variations. Anastrozole is predominantly metabolized by CYP3A4 and CYP3A5 enzymes. The objective of this study was to determine the impact of CYP3A4 and CYP3A5 genetic polymorphisms on anastrozole’s pharmacokinetics and pharmacodynamics in postmenopausal breast cancer women. A total of 94 postmenopausal breast cancer women were recruited for this study. Patients’ socio-demographic data and clinical variables were recorded and blood samples were collected for DNA acquisition, hormonal and anastrozole serum levels. Genotyping of CYP3A418A and CYP3A53 was performed using the conventional polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), while that of CYP3A44, CYP3A418B and CYP3A422 was carried out by a novel multiplex PCR-RFLP method. Serum anastrozole concentration was determined by an ultra-high performance liquid chromatography (UHPLC) method using a simple solid-phase extraction procedure. Our study reported that CYP3A418B G>A has a high frequency (0.48) among Malaysians and that CYP3A418A T>C and CYP3A53A>G occur in low (0.03) and high (0.64) frequencies respectively among Malaysians. No variant alleles of CYP3A44 and CYP3A422 were detected among all the subjects. Patients homozygous for CYP3A418B G>A and CYP3A53 A>G had lower and higher anastrozole serum levels respectively compared to those having the respective wild types or heterozygous variants. The multiplex PCR-RFLP method for the simultaneous detection of CYP3A44 A>G, CYP3A418B G>A and CYP3A422 C>T, was applied in genotyping of all the subjects. The newly developed UHPLC method demonstrated a good linearity over concentration ranges of 20 – 1600 ng/mL. The mean recovery for anastrozole was 88.17% with a limit of quantitation of 20 ng/ml. Variables such as patients’ age and time since commencement of anastrozole therapy were associated with higher risk of developing vasomotor symptoms and mood disturbances and/or vaginal dryness/dyspareunia respectively. No significant association was established between CYP3A4 and CYP3A5 genetic polymorphisms and anastrozole’s pharmacodynamics. The detected CYP3A418B G>A and CYP3A5*3 A>G alleles may serve as an important biomarkers of altered anastrozole metabolism in breast cancer patients receiving anastrozole in future.
format	Thesis
qualification_name	Doctor of Philosophy (PhD.)
qualification_level	Doctorate
author	Abubakar, Murtala Bello
author_facet	Abubakar, Murtala Bello
author_sort	Abubakar, Murtala Bello
title	The impact of CYP3A4 and CYP3A5 polymorphisms on anastrozole's pharmacokinetics and pharmacodynamics in post-menopausal breast cancer patients
title_short	The impact of CYP3A4 and CYP3A5 polymorphisms on anastrozole's pharmacokinetics and pharmacodynamics in post-menopausal breast cancer patients
title_full	The impact of CYP3A4 and CYP3A5 polymorphisms on anastrozole's pharmacokinetics and pharmacodynamics in post-menopausal breast cancer patients
title_fullStr	The impact of CYP3A4 and CYP3A5 polymorphisms on anastrozole's pharmacokinetics and pharmacodynamics in post-menopausal breast cancer patients
title_full_unstemmed	The impact of CYP3A4 and CYP3A5 polymorphisms on anastrozole's pharmacokinetics and pharmacodynamics in post-menopausal breast cancer patients
title_sort	impact of cyp3a4 and cyp3a5 polymorphisms on anastrozole's pharmacokinetics and pharmacodynamics in post-menopausal breast cancer patients
granting_institution	Universiti Sains Malaysia
granting_department	Pusat Pengajian Sains Perubatan
publishDate	2017
url	http://eprints.usm.my/43133/1/Dr._Murtala_Bello_Abubakar-24_pages.pdf
_version_	1747821171406012416

The impact of CYP3A4 and CYP3A5 polymorphisms on anastrozole's pharmacokinetics and pharmacodynamics in post-menopausal breast cancer patients

Similar Items